Loroblis®
Composition
One Loroblis® Oro dispersible tablet contains (minimum) 1 × 109 CFU Streptococcus salivarius K12 (BLIS K12).
Streptococcus salivarius K12 is a bacterial strain that colonizes the oral cavity and nasopharynx of healthy individuals and is part of the normal bacterial flora.
Mechanism of action
Although a common bacterial strain, Streptococcus salivarius K12 produces 2 bacteriocins: the antimicrobial peptides Salivaricin A2 and Salivaricin B, which have the potential to inhibit the development of pathogenic bacterial strains, responsible for bacterial pharyngitis and tonsillitis, acute otitis media and halitosis (e.g., Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis).
In addition to the potential to maintain and restore eubiosis in the oral cavity and pharynx, Streptococcus salivarius K12 has antiviral activity, anti-inflammatory activity and antifungal properties, supported by in vitro and in vivo studies.
Recommendation
Clinical studies have shown that Loroblis® contributes to the maintenance and development of a microbial flora with a protective role in the oral cavity and pharynx, with potential in:
– Prophylaxis of upper respiratory tract infections (pharyngitis, tonsillitis, otitis media);
– Therapy for mild and moderate upper respiratory tract infections;
– Therapy of oral inflammatory diseases (stomatitis, gingivitis, candidiasis, halitosis);
– Supportive therapy after antibiotic treatment of upper respiratory tract infections.
Administration method
Loroblis® is recommended for adults and children older than 3 years: 1 Oro dispersible tablet / day, slowly dissolved in the oral cavity, evening after oral hygiene, depending on your doctor’s recommendation, up to 1 Oro dispersible tablet / day for 90 days for the prophylaxis of recurrent infections of the upper respiratory tract (pharyngitis, tonsillitis, recurrent otitis media).
Co-administration of Loroblis® with antibiotics is unnecessary due to the strong antibiotic sensitivity of Streptococcus salivarius K12;
Immunocompromised individuals undergoing certain treatments (chemotherapy, radiation therapy) or severe leukopenia should consult a physician prior to administration of the product.